GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vaccinex VCNX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.97

+8.26%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Vaccinex — daily VCNX Delayed
Market value
$2.6m
Last close × shares
Volume
1.1k
Shares, 20 Nov 2026

About Vaccinex

From its filings with the US Securities and Exchange Commission

SEC filings

Vaccinex is based in Rochester, New York and is incorporated in Delaware. Its shares trade on OTC under the ticker VCNX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $601,000 and a net loss of $18.6m. At that date it held total assets of $2.6m and shareholders' equity of −$2.5m.

In its own words

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the activity of immune and inflammatory cells at sites of injury, cancer, or infection. We have used our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. We are focused on developing pepinemab for the treatment of Alzheimer’s disease, or AD and as our resources allow, also developing pepinemab for head and neck cancer, and pancreatic cancer. Additionally, third party investigators have studied pepinemab in clinical trials in breast cancer, as well as in “window of opportunity” studies in other indications, including melanoma. We have developed multiple proprietary platform technologies and product candidates to address serious diseases or conditions that have a substantial impact on day-to-day functioning and for which treatment is not addressed adequately by available therapies.

Quoted from its 10-K, filed 15 Apr 2025. Read the filing on SEC.gov ↗

More about Vaccinex →

Latest on Vaccinex

Our reporting

We have not reported on Vaccinex yet.

Next results

6 Apr 2027

Due on 6 Apr 2027. Analysts expect earnings of -60.90 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Vaccinex's ticker?

Vaccinex trades as VCNX on its US listing, under ISIN US9186403013.

What was Vaccinex's last closing price?

0.97 on 20 Nov 2026. The figure is in USD and is never converted.

When does Vaccinex next report results?

Results are expected on 16 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.